Mizuho analyst Steven Valiquette raised the firm’s price target on Cencora (COR) to $340 from $334 and keeps an Outperform rating on the shares. The firm cites a “slightly better” specialty and European drug outlook for the target bump ahead of the Q3 report.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COR:
- Cencora price target raised to $380 from $350 at UBS
- Trump Trade: Trump administration prepares new probe into pharma prices
- Trump admin prepares new probe into U.S. pharma prices, FT says
- Cencora price target raised to $334 from $316 at Mizuho
- Cencora added to ‘Tactical Outperform’ list at Evercore ISI